CARdiomyopathy in type 2 DIAbetes mellitus (CARDIATEAM Project)
Research type
Research Study
Full title
Cardiomyopathy in Type 2 diabetes mellitus.
IRAS ID
279435
Contact name
Chim Lang
Contact email
Sponsor organisation
University of Dundee -Tayside Academic Science Collaboration
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 0 months, 30 days
Research summary
The frequent co-existence of aging, hypertension, obesity and type 2 diabetes mellitus (T2DM) contributes to cardiac dysfunction (inefficiency of heart pump function). It is not known if this cardiac dysfunction is triggered by the disease of diabetes alone or is it from a combination of all these other factors. This cardiac dysfunction has been referred to as diabetic cardiomyopathy (DCM). These confounding factors are potentially associated with a progressive decline in heart pump function, an alteration in the stiffness of the heart, and left ventricular hypertrophy (an increase in thickness of the heart). Furthermore, systemic inflammation and activation of the immune system can drive this cardiac dysfunction and progression to a form of heart failure(HF) called HF with preserved ejection fraction (HFpEF). This may involve a number of disease processes such as heart blood vessel dysfunction and fibrosis (scarring ) of the heart. Finally, the role of genetics in the development of LV Hypertrophy and increased HF risk is not known. The aim of this study is to explore in detail the respective role of all these different confounders on the cardiac changes observed in T2DM and ultimately the determine whether the uniqueness and the disease of DCM.
REC name
East Midlands - Derby Research Ethics Committee
REC reference
20/EM/0228
Date of REC Opinion
12 Nov 2020
REC opinion
Further Information Favourable Opinion